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Iliac artery angioplasty and iliac artery stenting
have been established as viable alternatives to treat-
ing aortoiliac occlusive disease in some patients.1
More patients are undergoing endovascular proce-
dures because of the relative noninvasiveness com-
pared with surgery.2 As the number of endovascular
procedures rises, the associated risk factors for stent
failure have been analyzed by several investigators;
medical risk factors, the patient’s sex, presenting
lesion, and distal runoff are a few factors. However,
one risk factor that has been analyzed is the anatom-
ic location of stent placement: the common iliac
artery (CIA) versus the external iliac artery (EIA).
The interest in the effect anatomic location has on
stent patency is that EIAs are smaller in diameter
with lower flow velocities compared with CIAs.3
Also, Johnston4 showed that percutaneous translu-
minal angioplasty (PTA) in the EIA had poorer
patency rates when compared with PTA in the CIA.
When analyses were performed in the patency
rates of primary stents in the EIA versus the CIA,
results were conflicting. The effect of anatomic loca-
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Purpose: Placement of intraluminal stents in the common iliac artery (CIA) and external
iliac artery (EIA) has become an accepted therapy for treating localized arterial stenoses.
The purpose of this study was to compare anatomic patency rates of stents placed in the
EIA and CIA for occlusive disease.
Methods: A radiologic computer database was used to identify 69 consecutive male
patients at the Minneapolis Veterans Affairs Medical Center from February 1, 1993,
through January 31, 1999, who underwent placement of 98 stents (82 Wallstents and
16 Palmaz stents) for physiologically significant iliac artery occlusive disease and vary-
ing degrees of chronic limb ischemia. Patients were followed up with surveillance duplex
ultrasound scanning examinations 1 day after procedure, 3 months after procedure, and
then at 6-month intervals after stent placement. Follow-up angiograms were performed
for patients with duplex ultrasound scans that revealed velocities greater than 300 cm/s.
Patient risk factors, iliac artery runoff, concomitant outflow procedures, and anatomic
patency rates were compared between patients receiving EIA stents and those receiving
CIA stents.
Results: The mean age for the EIA stent group was 69 ± 1 years versus 66 ± 1 years (P =
.03) for the CIA stent group. Mean follow-up was 21.4 ± 2.1 months (± SE) for all
patients. Patients with EIA stents had more ischemic lower limbs when compared with
patients who had CIA stents (P = .05). No differences were found between groups in risk
factor analysis (P = not significant). Lesion lengths were similar between groups: EIA, 4.6
± 0.6 cm, and CIA, 5.3 ± 0.8 cm (P = not significant). The following differences were
noted on primary patency rates (EIA group vs CIA group): 1 year (93% vs 88%), 2 years
(91% vs 85%), and 3 years (90% vs 78%) (Cox proportional hazards; P = .13).
Conclusions: Anatomic patency rates for EIA and CIA stents appear to be similar despite
the fact that patients with EIA stents were older and had more ischemic limbs compared
with the patients who had CIA stents. (J Vasc Surg 2000;31:889-94.)
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tion on stent patency in multivariate analyses in sev-
eral studies has failed to show statistical difference.5,6
In other studies, Laborde et al7 showed that an
anatomic effect was found in stent patency rates
when stents were placed in type 3 aortoiliac disease,
as compared with type 2 or type 1 disease, and
Sullivan et al8 showed that stent patency was deter-
mined by anatomic location.
On an anatomic and pathologic basis we would
expect that EIA stents have lower patency rates than
CIA stents. The EIA is smaller in diameter and, in
our experience, more likely to have diffuse disease
when compared with the CIA. Several studies have
shown that female sex is a prognostic indicator of
poor iliac stent patency rates, probably because of
smaller caliber iliac arteries.6,7 If the results of small-
er caliber vessels affecting stent patency were to be
extrapolated, the EIA should predict lower patency
rates in stents compared with patency rates in stents
placed in the CIA. In this study, we used a male
patient population to primarily examine the
anatomic patency rates of stents placed in the EIA
versus the anatomic patency rates of stents placed in
the CIA.
PATIENTS AND METHODS
A radiology computer database was used to iden-
tify consecutive patients who underwent successful
placement of iliac artery stents for aortoiliac occlu-
sive disease at the Minneapolis Veterans Affairs
Medical Center from February 1993 through
January 1998. Patients who had a failed attempt at
stent placement were not captured in the radiologic
database and could not be included in the analysis.
February 1993 was the initiation of departmental
policy where all patients would undergo a combined
therapy of angioplasty and stenting rather than
attempts at angioplasty alone. All patients were
prospectively followed up, whereas stent patency,
patient survival, and individual patient data were col-
lected from a retrospective chart review.
All stents were placed in the angiography suite in
the radiology department by interventional radiolo-
gists after consultation with the attending vascular
surgeon. A total of 98 stents were deployed in 95
limbs for hemodynamically significant stenoses in
the EIA and the CIA.
All examinations were performed with angiogra-
phy by means of an ipsilateral or contralateral
femoral approach. Patients were given 5000 units of
heparin before stent placement, and a 7-French or 8-
French introducer sheath was used for stent deploy-
ment. A stenosis was deemed significant if the gradi-
ent across the lesion was 10 mm Hg at rest, if the
gradient across the lesion was 15 mm Hg after the
administration of 30 mg of papaverine, or if the
angiographic catheter caused occlusion or near
occlusion of the artery as it crossed the lesion.
Eighty-two Wallstents (Boston Scientific Vascular,
Boston, Mass) and 16 Palmaz stents (Cordis
Corporation, Miami, Fla) were placed in all patients.
For tight lesions that required Wallstent placement,
predilation with a 6- or 8-mm balloon was performed.
After Wallstent deployment, the stenosis was dilated
with a 6-, 8-, or 10-mm balloon.
For Palmaz deployment, no predilation was per-
formed if the guiding catheter crossed the stenosis
easily. If the lesion was severe, predilation was per-
formed using a 6-mm balloon. The stent was
deployed with 6-, 8-, or 10-mm balloons.
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Fig 1. A Cox proportions hazards model for patient sur-
vival corrected for age (P = .77).
Table I. A multivariate logistic regression compar-
ing risk factors in patient groups: EIA stent group
and CIA stent group
Estimated
Risk factor relative risk 95% CI P value
Age 1.1 1.0-1.2 .03
Cardiac .99 .63-1.53 .95
Diabetes 1.35 .69-2.66 .37
Hypertension .64 .36-1.14 .13
Renal 2.33 .34-16.09 .39
Lipids .75 .48-1.17 .21
Pulmonary .76 .44-1.30 .31
Smoking 1.11 .70-1.78 .65
Deployment was deemed technically successful if
there was less than a 30% residual stenosis. Patients
were then followed up with serial duplex ultrasound
scanning examinations: 1 day after procedure, 3
months after procedure, and at 6-month intervals
after stent placement. If peak systolic velocities were
greater than 300 cm/s on duplex ultrasound scan-
ning during the follow-up period, an angiogram was
performed. Indications for reintervention were a
stenosis greater than 60% and a gradient greater than
15 mm Hg with papaverine or greater than 10 mm
Hg at rest.
Patient risk factors were also obtained by a chart
review that included age, cardiac disease, diabetes,
hypertension, hypercoagulability, renal disease,
hyperlipidemia, pulmonary disease, and tobacco use.
Each risk factor was stratified from 0 (asymptomatic)
to 3 (severe disease) as described by Rutherford et
al.9 Clinical symptoms of lower limb ischemia were
evaluated using the modified clinical categories of
chronic limb ischemia for patients: 0 = asymptomatic,
1 = mild claudication, 2 = moderate claudication, 3 =
severe claudication, 4 = ischemic rest pain, 5 = minor
tissue loss, and 6 = major tissue loss.9
Vessel runoff from the CIA and the EIA was eval-
uated by assessing runoff in the common femoral
artery, superficial femoral artery (SFA), and the deep
femoral artery. Patients with less than 50% stenosis in
any runoff vessel were considered to have good
runoff. Patients who underwent an infrainguinal
bypass graft procedure (eg, femorofemoral,
femoropopliteal, femoral-distal bypass graft) within
30 days of stent placement were considered to have a
“concomitant procedure” to maximize distal runoff.
Patency rates and survival rates were calculated
using the Cox proportional hazards model. Discrete
variables were evaluated using the χ2 analysis and the
Fisher exact test where applicable. A multivariate
logistic regression analysis was used to evaluate
patient risk factors, and a Mann-Whitney U test was
used to evaluate differences in clinical symptoms
between groups. Because the outcomes of successful-
ly deployed iliac stents were retrospectively reviewed,
an intention to treat analysis could not be performed.
Records of patients excluded from stenting were not
available for review. Statistical significance was
defined as a P value less than .05. A microcomputer
statistical package (SPSS 9.0; SPSS Science, Chicago,
Ill) was used to carry out all statistical analyses.
RESULTS
During the period from February 1993 through
January 1998, 98 iliac artery stents were placed in 69
consecutive male patients at the Minneapolis
Veterans Affairs Medical Center. The mean age in the
EIA stent group (n = 49) was 69 ± 1 (± SE) years,
significantly higher than the mean age in the CIA
stent group (n = 31), 66 ± 1 years (P = .03). A total
of 98 stents were deployed in 69 patients. Multiple
stents were placed in 27 (39%) of our 69 patients for
multiple iliac stenoses. In the EIA group, 11 patients
had EIA stents placed in both the right and left EIA,
and three patients had two stents placed in the same
EIA segment. In the CIA group, four patients had
CIA stents placed in both the right and left CIA, and
two patients had two stents placed in the same CIA
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Table II. Categories of chronic limb ischemia between EIA stent group and CIA stent group*
Ischemia category 0 1 2 3 4 5 6 Mean Median†
EIA stent (61 stents) 4 2 11 13 12 9 10 3.72 4
CIA stent (37 stents) 4 4 8 7 10 3 1 2.91 3
*The EIA stent group had more severe ischemia levels by category.
†P = .05.
Table III. Proportion of patients with runoff and concomitant outflow procedure between groups 
CFA runoff SFA runoff DFA runoff Outflow procedure
EIA 51/61 (84%) 20/61 (33%) 40/61 (66%) 11/61 (18%)
CIA 29/37 (78%) 17/37 (46%) 25/37 (68%) 12/37 (32%)
P value .84 .39 .93 .20
CFA, Common femoral artery; CIA, common iliac artery; DFA, deep femoral artery; EIA, external iliac artery; SFA, superficial femoral
artery.
segment. Five patients had both CIA and EIA stents
placed in the ipsilateral side, and two patients had
both bilateral CIA and EIA stents placed. The over-
all follow-up period was 21.4 ± 2.1 months. There
was no significant difference with regard to patient
risk factors (Table I). Patients in the EIA stent group
had more severe ischemic disease with a median
chronic ischemia score of 4 (mean = 3.72), “ischemic
rest pain,” compared with the CIA group, which had
a median chronic ischemia score of 3 (mean = 2.91),
“severe claudication.”(Mann-Whitney U test; P =
.05; Table II). Eight stents were deployed in four
EIAs and four CIAs of asymptomatic limbs in the
course of angiography for other vascular diseases.
The following are examples: (1) During access for a
cerebral angiogram, the catheter crossed a near
occlusive lesion at the proximal EIA, which was
stented to prevent distal thrombosis, and (2) there
was a high-grade CIA lesion proximal to an infrain-
guinal bypass graft where low graft flow was first
detected on graft surveillance. Fewer stents were
placed in the EIA (six [9.8%] of 61 stents) for occlu-
sion when compared with stents placed in the CIA
(11 [29.7%] of 37 stents) (χ2; P = .04). However,
only one of the stents placed in the CIA for occlusion
failed during the follow-up period.
The average lesion length between the EIA and
the CIA was similar between groups: EIA (4.6 ± 0.6
cm) versus CIA (5.3 ± 0.8 cm) (P = not significant).
The average size of artery diameter (based on the
balloon size used proximal to the lesion) between
the EIA and the CIA was different: EIA (7.81 ± 0.1
mm) versus CIA (8.36 ± 0.2 mm) (P = .002). There
were no differences between the EIA stent group
and CIA stent group with respect to runoff in the
SFA, common femoral artery, or deep femoral
artery. No differences were found between the
groups with respect to the number of concomitant
outflow procedures performed to maintain patency
of the iliac stent (Table III).
After the correction for age, cumulative patient
survival was not statistically different between the two
groups (Cox proportional hazards; P = .77) as shown
in Fig 1. Also, there was no statistical difference
between primary patency rates for the EIA stent group
versus the CIA stent group at 1 year (93% vs 88%), 2
years (91% vs 85%), and 3 years (90% vs 78%) (Cox
proportional hazards; P = .13) as shown in Fig 2.
DISCUSSION
The use of endovascular stents and PTA in the
aortoiliac system has become an accepted therapy for
patients with aorto-occlusive disease.1,2,10 As with
any new treatment modality, the roles and indications
for iliac artery stenting continue to evolve. When is a
patient appropriate for surgery versus stenting?6,11
Female sex, SFA occlusion, perioperative vascular
complications, and hypercholesterolemia were found
by Ballard et al6 to be risk factors for lower patency
rates in iliac artery stents. However, in their multi-
variate analysis, they failed to show that stent location
in the CIA versus the EIA made a difference in
patency rates. Treiman et al5 analyzed risk factors for
early stent failure and found no independent variable
in predicting success. In their study, SFA patency did
not correlate with outcome, nor did anatomic loca-
tion of the iliac artery stent.
However, other studies demonstrated that
anatomic location of iliac artery stents influenced
patency rates. The anatomic distribution of athero-
sclerosis has been described to follow one of three
anatomic patterns. Type 1 includes patients with
occlusive arterial disease limited to the distal abdom-
inal aorta and CIAs with good runoff. Type 2
includes patients with aortoiliac disease involving the
EIAs with good runoff. Type 3 includes patients
with disease extending to the femoral, popliteal, and
two or three calf arteries.7 A study by Laborde et al7
examined 455 patients according to the three types
of anatomic distribution of atherosclerosis. They
found that type 3 aortoiliac lesions had inferior 3-
year patency rates of 60.8% in type 3 disease versus
91.6% for type 1 and 97.9% for type 2 disease.
They also found female sex and periprocedural
complications decreased patency rates. The reason
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Fig 2. Primary patency rates of iliac artery stents by
anatomic location (P = .13). CIA, Common iliac artery;
EIA, external iliac artery.
for decreased patency rates in females may be relat-
ed to the differences in the diameter of the EIA and
CIA. Horejs et al3 describe the normal aortoiliac
diameters by computed tomography (CT) of men
and women in their 60s. For women, the CIA size is
9.7 mm, and the EIA/femoral artery size is 7.8 mm.
In men the size discrepancy is not as large. In the
same study, men in their 60s have a CIA size that is
11.7 mm and an EIA/femoral artery size that is
10.5 mm. The use of male patients in this study
would improve the chances that the EIA stents
could remain patent, to lessen the size bias dis-
crepant between the CIA and the EIA. When ana-
lyzing the size differences between the CIA and the
EIA in our patients, we found the CIA to be larger
in caliber than the EIA (8.36 mm vs 7.81 mm; P =
.002). Any conclusions drawn from the patency rate
results comparing EIA and CIA stents in this study
should be taken with caution when applying these
results to the female patient.
Sullivan et al8 evaluated outcomes of 288
patients and found that the degree of initial stenosis
and SFA patency were associated with long-term
patency. However, in their evaluation of the effect of
anatomic location on stent patency, they found that
a significant difference in patency rates exists
between EIA stents and CIA stents when measuring
thigh-brachial indices (TBIs).
To date, researchers of all the studies primarily
examined risk factors and their effect on patency in
multivariate analyses. Prior studies may have failed to
detect a true difference in patency rates (type 2
error) on the basis of anatomic location when a true
difference existed.
In this study, we attempted to answer one ques-
tion: Do EIA stents have lower anatomic patency
rates than CIA stents? To simplify our analysis, we
examined only anatomic patency based on angio-
graphic or duplex ultrasound scanning data. Ahn et
al12 describe the use of clinical, hemodynamic, and
anatomic (angiographic) data to standardize patency
rates of endovascular procedures between reports.
However, because of the multilevel nature of athero-
sclerosis in infrainguinal ischemia, any hemodynam-
ic (TBI) comparison of patency rates between EIA
and CIA stents may cloud results. Sullivan et al,8 in
examining stent patency, found changes in TBI but
apparently could not find a difference in other para-
meters when comparing EIA and CIA stent patency
rates.
At the Minneapolis Veterans Affairs Medical
Center, more patients have disease in the EIA (n =
49) than in the CIA (n = 31). Because all patients
underwent primary stenting for an iliac artery lesion
after February 1993, we were able to analyze the
data without the influence of failed PTA on stent
patency outcomes. In comparing vessel angiography
at the time of stent placement, we found that 11
(29.7%) of 37 stents were placed in occluded CIAs
versus 6 (9.8%) of 61 stents placed in the EIAs.
Because only one stent from all stents placed for
occlusion failed during the follow-up period, we
believe that placing more stents in occluded CIAs
than EIAs did not adversely affect our comparison.
In our analysis, we found that no difference in
patency rates could be detected between EIA and
CIA stents. A power analysis was performed to
determine whether a type 2 error was committed in
this study. We conservatively assumed that if there
were a true difference of 10% in anatomic patency
between EIA stents and CIA stents, one might con-
sider abandoning the placement of EIA stents. (A
smaller difference in stent patency requires more
patients to achieve the same power.) This study has
a 92% power of detecting this 10% difference to a P
value of less than .05. Obviously, greater differences
in patency rates between the EIA and the CIA
would imply that our study has a power greater than
92% to detect this difference.
CONCLUSIONS
We attempted to aggressively minimize type 2
error by focusing in on anatomic location of the stent
and anatomic patency with the use of angiography or
duplex ultrasound scanning. From this study, one can
be more confident that successfully placed EIA stents
can have patency rates comparable to CIA stents. The
effects of a stent on hemodynamic outcomes on a
limb are important factors, and these outcomes
should be measured in the future.
We thank Ms Connie M. Lindberg for her editorial
assistance in the preparation of the manuscript.
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THE DARTMOUTH ATLAS OF VASCULAR CARE
The Joint Council of the SVS/ISCVS has sponsored a project with the Center for the Evaluative
Clinical Sciences at Dartmouth Medical School to develop a national Atlas of Vascular Health Care.
The Dartmouth group is led by Dr John Wennberg, who pioneered geographic small area analysis, the
analytical foundation for the Dartmouth Atlas series. Based on 1996-1997 Medicare Part B (CPT)
claims data, the Atlas contains a comparison of the rates of peripheral vascular surgery and interven-
tional procedures across the 306 major hospital referral regions of the United States. The Atlas also
identifies the types of specialists performing these procedures in different referral regions (cardiolo-
gists, radiologists, cardiothoracic, general and board-certified vascular surgeons).
Procedures analyzed in the Atlas include carotid endarterectomy; abdominal aortic aneurysm
repair; lower extremity arterial bypass graft, angioplasty/stenting, and amputation; hemodialysis
access; and other miscellaneous procedures. Outcome of carotid and aortic surgery is analyzed by spe-
cialty and by surgeon volume. Data tables and a computer diskette provide detailed information con-
cerning rates and provider specialty type for each vascular procedure in each local region. A sophisti-
cated model of vascular workforce projection is also included. 
The Joint Council was pleased to provide financial support for this effort to better understand the
delivery of vascular health care in the United States. The Atlas is now available and may be ordered
from the publisher, the American Hospital Association (1-800-242-2626). Because of their sponsor-
ship, there is a reduced price for SVS/ISCVS members.
